Insider Trading Alert - BRCM, CI And AMRI Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Friday, Sept. 12, 2014, 84 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $100.00 to $10,031,220.00.

Highlighted Stocks Traded by Insiders:

Broadcom (BRCM) - FREE Research Report

Chong Arthur, who is Exec. V.P., G.C. & Secretary at Broadcom, sold 10,000 shares at $40.55 on Sept. 12, 2014. Following this transaction, the Exec. V.P., G.C. & Secretary owned 339,751 shares meaning that the stake was reduced by 2.86% with the 10,000-share transaction.

Timberman Terri L., who is EVP, Human Resources at Broadcom, sold 7,000 shares at $40.56 on Sept. 12, 2014. Following this transaction, the EVP, Human Resources owned 231,110 shares meaning that the stake was reduced by 2.94% with the 7,000-share transaction.

The shares most recently traded at $40.30, down $0.26, or 0.64% since the insider transaction. Historical insider transactions for Broadcom go as follows:

  • 4-Week # shares sold: 74,700
  • 12-Week # shares sold: 123,606
  • 24-Week # shares sold: 258,672

The average volume for Broadcom has been 6.5 million shares per day over the past 30 days. Broadcom has a market cap of $22.0 billion and is part of the technology sector and electronics industry. Shares are up 36.21% year-to-date as of the close of trading on Friday.

Broadcom Corporation provides semiconductor solutions for wired and wireless communications. Its products offer voice, video, data, and multimedia connectivity in the home, office, and mobile environments. The stock currently has a dividend yield of 1.18%. The company has a P/E ratio of 36.7. Currently, there are 22 analysts who rate Broadcom a buy, 1 analyst rates it a sell, and 7 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BRCM - FREE

TheStreet Quant Ratings rates Broadcom as a buy. The company's strengths can be seen in multiple areas, such as its compelling growth in net income, largely solid financial position with reasonable debt levels by most measures, expanding profit margins, solid stock price performance and notable return on equity. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Broadcom Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Cigna (CI) - FREE Research Report

Henney Jane E Md, who is Director at Cigna, sold 475 shares at $95.98 on Sept. 12, 2014. Following this transaction, the Director owned 14,000 shares meaning that the stake was reduced by 3.28% with the 475-share transaction.

The shares most recently traded at $91.83, down $4.15, or 4.52% since the insider transaction. Historical insider transactions for Cigna go as follows:

  • 4-Week # shares sold: 11,475
  • 12-Week # shares sold: 17,458
  • 24-Week # shares sold: 50,662

The average volume for Cigna has been 1.4 million shares per day over the past 30 days. Cigna has a market cap of $24.6 billion and is part of the health care sector and health services industry. Shares are up 5.53% year-to-date as of the close of trading on Friday.

Cigna Corporation, a health services organization, provides insurance and related products and services in the United States and internationally. The stock currently has a dividend yield of 0.04%. The company has a P/E ratio of 12.8. Currently, there are 8 analysts who rate Cigna a buy, no analysts rate it a sell, and 7 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CI - FREE

TheStreet Quant Ratings rates Cigna as a buy. The company's strengths can be seen in multiple areas, such as its increase in net income, revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity and good cash flow from operations. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full Cigna Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Albany Molecular Research (AMRI) - FREE Research Report

D Ambra Constance M, who is 10% Owner at Albany Molecular Research, sold 20,000 shares at $20.12 on Sept. 12, 2014. Following this transaction, the 10% Owner owned 2.6 million shares meaning that the stake was reduced by 0.76% with the 20,000-share transaction.

D Ambra Thomas E Phd, who is Chairman, Board of Directors at Albany Molecular Research, sold 20,000 shares at $20.12 on Sept. 12, 2014. Following this transaction, the Chairman, Board of Directors owned 2.8 million shares meaning that the stake was reduced by 0.72% with the 20,000-share transaction.

The shares most recently traded at $22.07, up $1.95, or 8.84% since the insider transaction. Historical insider transactions for Albany Molecular Research go as follows:

  • 4-Week # shares bought: 10,000
  • 4-Week # shares sold: 2,500
  • 12-Week # shares bought: 10,000
  • 12-Week # shares sold: 88,297
  • 24-Week # shares bought: 40,000
  • 24-Week # shares sold: 99,194

The average volume for Albany Molecular Research has been 399,800 shares per day over the past 30 days. Albany Molecular Research has a market cap of $710.3 million and is part of the health care sector and drugs industry. Shares are up 116.57% year-to-date as of the close of trading on Friday.

Albany Molecular Research, Inc., a contract research and manufacturing company, provides integrated drug discovery, development, and manufacturing services primarily in the United States, Europe, and Asia. The company has a P/E ratio of 43.7. Currently, there are 2 analysts who rate Albany Molecular Research a buy, 1 analyst rates it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on AMRI - FREE

TheStreet Quant Ratings rates Albany Molecular Research as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, revenue growth and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Albany Molecular Research Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Replay: Jim Cramer on the Markets, 10-Year Yield, Oil Prices and Foot Locker

Replay: Jim Cramer on the Markets, 10-Year Yield, Oil Prices and Foot Locker

Video: You Could Live in a Ritz-Carlton or St. Regis Home

Video: You Could Live in a Ritz-Carlton or St. Regis Home